Cronos Group (CRON) vs Ironwood Pharmaceuticals (IRWD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Ironwood Pharmaceuticals (IRWD) has outperformed Cronos Group (CRON) over the past year, gaining 146.7% versus a gain of 23.7%. Over five years, CRON leads with a -40.9% price change compared with -72.5% for IRWD. Cronos Group is the larger company by market cap ($1.19 billion vs $639.5 million), about 1.9 times the size.
On valuation, Ironwood Pharmaceuticals trades at a lower trailing P/E (5.0x vs 16.9x for Cronos Group).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRON | IRWD |
|---|---|---|
| Share price | $3.22 | $3.87 |
| Market cap | $1.19B | $639.48M |
| 1-day change | -0.62% | +3.20% |
| YTD return | +23.19% | +11.28% |
| 1-year return | +23.66% | +146.71% |
| 5-year return | -40.88% | -72.55% |
| P/E ratio (TTM) | 16.95 | 5.03 |
| Forward P/E | — | 2.58 |
| EPS (TTM) | $0.19 | $0.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.61 | $5.78 |
| 52-week low | $2.28 | $1.41 |
| Distance from 52-week high | -10.75% | -33.04% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | -23.60% | +57.62% |
| Average volume | 1.13M | 2.03M |
| Shares outstanding | 368.41M | 165.24M |
| Employees | 610 | 100 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRWD has outperformed CRON by 123.0 percentage points over the past year.
- Cronos Group trades at a higher earnings multiple (16.9x vs 5.0x trailing P/E).
About Cronos Group
CRON stock →Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names.
Health Care · Medicinal Chemicals and Botanical Products · 610 employees
About Ironwood Pharmaceuticals
IRWD stock →Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
CRON vs IRWD FAQ
Which is bigger, Cronos Group or Ironwood Pharmaceuticals?
Cronos Group (CRON) is larger, with a market capitalization of $1.19B compared with $639.48M for Ironwood Pharmaceuticals (IRWD).
Which stock has performed better over the past year, CRON or IRWD?
IRWD returned +146.71% over the past 12 months, compared with +23.66% for CRON (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CRON or IRWD?
IRWD has the lower trailing P/E at 5.0, versus 16.9 for CRON. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Cronos Group and Ironwood Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Medicinal Chemicals and Botanical Products for Cronos Group and Biotechnology: Pharmaceutical Preparations for Ironwood Pharmaceuticals.